Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon lambda + daclatasvir + asunaprevir
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
**pegylated interferon lambda + daclatasvir + asunaprevir** is an investigational triple combination regimen for chronic hepatitis C virus (HCV) infection. Pegylated interferon lambda is a type III interferon that selectively activates antiviral host responses via the interferon lambda receptor, with limited extrahepatic effects. Daclatasvir is a direct-acting antiviral and NS5A inhibitor, which disrupts the viral replication complex. Asunaprevir is an NS3/4A protease inhibitor that blocks viral polyprotein processing. The combination is designed to provide synergistic antiviral activity across different steps of the HCV lifecycle. Clinical trial evidence shows high sustained viral response (SVR12) rates, especially in HCV genotype 1b, and improved tolerability compared to older interferon-based therapies[1][5]. The combination has not been widely adopted, as interferon-free regimens are now standard of care.
- Other names
- PEG-IFN lambda + daclatasvir + asunaprevir
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))IFNLR (Interferon Lambda Receptor)
Beyond the preview
Go deeper on pegylated interferon lambda + daclatasvir + asunaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon lambda + daclatasvir + asunaprevir.